Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases.

ABSTRACT: Polycystic liver disease (PLD) is a rare genetic disorder characterised by progressive liver enlargement due to multiple cysts. The main symptoms are liver volume-related. Although randomised controlled trials have shown that somatostatin analogues (SSAs) reduce liver volume as well as symptoms, specific guidance on when and how to use SSAs in clinical practice is still lacking. A panel of 15 hepatologists and nephrologists developed practical guidance on SSA use, based on a systematic literature search, expert surveys, and clinical experience. This consensus was reached during a two-day workshop by the European Reference Network on Hepatological Diseases, using 11 predefined key questions and an iterative Delphi process. PLD patients with liver volume-related symptoms, diffuse disease, an

SUBMITTER: Heinrich S 

PROVIDER: S-EPMC12670357 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature